Law & Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Law & Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Anapol, Schwartz, Weiss, Cohan, Feldman & Smalley
Anapol Schwartz Attorney Representing Trasylol(R) Victims Says Medical Study - Confirming Heart Bypass Drug Mortality Risk - to Open Floodgates for More Litigation
March 8th, 2008
According to Anapol Schwartz attorney James Ronca (http://www.anapolschwartz.com/attorneys/jim_ronca.shtml), a New England Journal of Medicine study (http://content.nejm.org/cgi/content/short/358/8/771'query=TOC) (to be released in the February 21, 2008, print edition) confirms that Bayer AG's blood-clotting drug Trasylol(R), used in coronary artery bypass graft (CABG) procedures, causes kidney/renal failure and increases mortality risk. While initial findings of the study, commissioned by Bayer, were sent to the drug company and the FDA in 2006, this is the first time the final results have been published in full. Ronca, who is one of...
Source: Law & Health Weekly (2008-03-08)
|
